523 related articles for article (PubMed ID: 34941392)
1. Dietary fiber and probiotics influence the gut microbiome and melanoma immunotherapy response.
Spencer CN; McQuade JL; Gopalakrishnan V; McCulloch JA; Vetizou M; Cogdill AP; Khan MAW; Zhang X; White MG; Peterson CB; Wong MC; Morad G; Rodgers T; Badger JH; Helmink BA; Andrews MC; Rodrigues RR; Morgun A; Kim YS; Roszik J; Hoffman KL; Zheng J; Zhou Y; Medik YB; Kahn LM; Johnson S; Hudgens CW; Wani K; Gaudreau PO; Harris AL; Jamal MA; Baruch EN; Perez-Guijarro E; Day CP; Merlino G; Pazdrak B; Lochmann BS; Szczepaniak-Sloane RA; Arora R; Anderson J; Zobniw CM; Posada E; Sirmans E; Simon J; Haydu LE; Burton EM; Wang L; Dang M; Clise-Dwyer K; Schneider S; Chapman T; Anang NAS; Duncan S; Toker J; Malke JC; Glitza IC; Amaria RN; Tawbi HA; Diab A; Wong MK; Patel SP; Woodman SE; Davies MA; Ross MI; Gershenwald JE; Lee JE; Hwu P; Jensen V; Samuels Y; Straussman R; Ajami NJ; Nelson KC; Nezi L; Petrosino JF; Futreal PA; Lazar AJ; Hu J; Jenq RR; Tetzlaff MT; Yan Y; Garrett WS; Huttenhower C; Sharma P; Watowich SS; Allison JP; Cohen L; Trinchieri G; Daniel CR; Wargo JA
Science; 2021 Dec; 374(6575):1632-1640. PubMed ID: 34941392
[TBL] [Abstract][Full Text] [Related]
2. Adjunctive Probiotic
Gao G; Ma T; Zhang T; Jin H; Li Y; Kwok LY; Zhang H; Sun Z
Front Immunol; 2021; 12():772532. PubMed ID: 34970262
[TBL] [Abstract][Full Text] [Related]
3. Gut Bacteria Composition Drives Primary Resistance to Cancer Immunotherapy in Renal Cell Carcinoma Patients.
Derosa L; Routy B; Fidelle M; Iebba V; Alla L; Pasolli E; Segata N; Desnoyer A; Pietrantonio F; Ferrere G; Fahrner JE; Le Chatellier E; Pons N; Galleron N; Roume H; Duong CPM; Mondragón L; Iribarren K; Bonvalet M; Terrisse S; Rauber C; Goubet AG; Daillère R; Lemaitre F; Reni A; Casu B; Alou MT; Alves Costa Silva C; Raoult D; Fizazi K; Escudier B; Kroemer G; Albiges L; Zitvogel L
Eur Urol; 2020 Aug; 78(2):195-206. PubMed ID: 32376136
[TBL] [Abstract][Full Text] [Related]
4. Improvement of PD-1 Blockade Efficacy and Elimination of Immune-Related Gastrointestinal Adverse Effect by mTOR Inhibitor.
Bai X; Wang X; Ma G; Song J; Liu X; Wu X; Zhao Y; Liu X; Liu Z; Zhang W; Zhao X; Zheng Z; Jing J; Shi H
Front Immunol; 2021; 12():793831. PubMed ID: 34987517
[TBL] [Abstract][Full Text] [Related]
5. Pectin supplement significantly enhanced the anti-PD-1 efficacy in tumor-bearing mice humanized with gut microbiota from patients with colorectal cancer.
Zhang SL; Mao YQ; Zhang ZY; Li ZM; Kong CY; Chen HL; Cai PR; Han B; Ye T; Wang LS
Theranostics; 2021; 11(9):4155-4170. PubMed ID: 33754054
[No Abstract] [Full Text] [Related]
6. The Effect of Athletes' Probiotic Intake May Depend on Protein and Dietary Fiber Intake.
Son J; Jang LG; Kim BY; Lee S; Park H
Nutrients; 2020 Sep; 12(10):. PubMed ID: 32992898
[TBL] [Abstract][Full Text] [Related]
7. Probiotics
Wang T; Zheng N; Luo Q; Jiang L; He B; Yuan X; Shen L
Front Immunol; 2019; 10():1235. PubMed ID: 31214189
[TBL] [Abstract][Full Text] [Related]
8. Gut microbiome modulates response to anti-PD-1 immunotherapy in melanoma patients.
Gopalakrishnan V; Spencer CN; Nezi L; Reuben A; Andrews MC; Karpinets TV; Prieto PA; Vicente D; Hoffman K; Wei SC; Cogdill AP; Zhao L; Hudgens CW; Hutchinson DS; Manzo T; Petaccia de Macedo M; Cotechini T; Kumar T; Chen WS; Reddy SM; Szczepaniak Sloane R; Galloway-Pena J; Jiang H; Chen PL; Shpall EJ; Rezvani K; Alousi AM; Chemaly RF; Shelburne S; Vence LM; Okhuysen PC; Jensen VB; Swennes AG; McAllister F; Marcelo Riquelme Sanchez E; Zhang Y; Le Chatelier E; Zitvogel L; Pons N; Austin-Breneman JL; Haydu LE; Burton EM; Gardner JM; Sirmans E; Hu J; Lazar AJ; Tsujikawa T; Diab A; Tawbi H; Glitza IC; Hwu WJ; Patel SP; Woodman SE; Amaria RN; Davies MA; Gershenwald JE; Hwu P; Lee JE; Zhang J; Coussens LM; Cooper ZA; Futreal PA; Daniel CR; Ajami NJ; Petrosino JF; Tetzlaff MT; Sharma P; Allison JP; Jenq RR; Wargo JA
Science; 2018 Jan; 359(6371):97-103. PubMed ID: 29097493
[TBL] [Abstract][Full Text] [Related]
9. Targeting PD-L2-RGMb overcomes microbiome-related immunotherapy resistance.
Park JS; Gazzaniga FS; Wu M; Luthens AK; Gillis J; Zheng W; LaFleur MW; Johnson SB; Morad G; Park EM; Zhou Y; Watowich SS; Wargo JA; Freeman GJ; Kasper DL; Sharpe AH
Nature; 2023 May; 617(7960):377-385. PubMed ID: 37138075
[TBL] [Abstract][Full Text] [Related]
10. Gut Microbiome Modulation Via Fecal Microbiota Transplant to Augment Immunotherapy in Patients with Melanoma or Other Cancers.
McQuade JL; Ologun GO; Arora R; Wargo JA
Curr Oncol Rep; 2020 Jun; 22(7):74. PubMed ID: 32577835
[TBL] [Abstract][Full Text] [Related]
11. The Microbiome in Advanced Melanoma: Where Are We Now?
Fortman DD; Hurd D; Davar D
Curr Oncol Rep; 2023 Sep; 25(9):997-1016. PubMed ID: 37269504
[TBL] [Abstract][Full Text] [Related]
12. Gut Microbiota and Therapy in Metastatic Melanoma: Focus on MAPK Pathway Inhibition.
Guardamagna M; Berciano-Guerrero MA; Villaescusa-González B; Perez-Ruiz E; Oliver J; Lavado-Valenzuela R; Rueda-Dominguez A; Barragán I; Queipo-Ortuño MI
Int J Mol Sci; 2022 Oct; 23(19):. PubMed ID: 36233289
[TBL] [Abstract][Full Text] [Related]
13. Gut microbiota: impacts on gastrointestinal cancer immunotherapy.
Lau HCH; Sung JJ; Yu J
Gut Microbes; 2021; 13(1):1-21. PubMed ID: 33435800
[TBL] [Abstract][Full Text] [Related]
14. Conversion of unresponsiveness to immune checkpoint inhibition by fecal microbiota transplantation in patients with metastatic melanoma: study protocol for a randomized phase Ib/IIa trial.
Borgers JSW; Burgers FH; Terveer EM; van Leerdam ME; Korse CM; Kessels R; Flohil CC; Blank CU; Schumacher TN; van Dijk M; Henderickx JGE; Keller JJ; Verspaget HW; Kuijper EJ; Haanen JBAG
BMC Cancer; 2022 Dec; 22(1):1366. PubMed ID: 36585700
[TBL] [Abstract][Full Text] [Related]
15. Role of gut microbiome on immunotherapy efficacy in melanoma.
Bibbò S; Ianiro G; Giambò F; Settanni CR; Cammarota G; Gasbarrini A
Hum Vaccin Immunother; 2022 May; 18(3):1926759. PubMed ID: 34190675
[TBL] [Abstract][Full Text] [Related]
16. Association of a Mediterranean Diet With Outcomes for Patients Treated With Immune Checkpoint Blockade for Advanced Melanoma.
Bolte LA; Lee KA; Björk JR; Leeming ER; Campmans-Kuijpers MJE; de Haan JJ; Vila AV; Maltez-Thomas A; Segata N; Board R; Harries M; Lorigan P; de Vries EGE; Nathan P; Fehrmann R; Bataille V; Spector TD; Hospers GAP; Weersma RK
JAMA Oncol; 2023 May; 9(5):705-709. PubMed ID: 36795408
[TBL] [Abstract][Full Text] [Related]
17.
Griffin ME; Espinosa J; Becker JL; Luo JD; Carroll TS; Jha JK; Fanger GR; Hang HC
Science; 2021 Aug; 373(6558):1040-1046. PubMed ID: 34446607
[TBL] [Abstract][Full Text] [Related]
18. Fecal microbiota transplant promotes response in immunotherapy-refractory melanoma patients.
Baruch EN; Youngster I; Ben-Betzalel G; Ortenberg R; Lahat A; Katz L; Adler K; Dick-Necula D; Raskin S; Bloch N; Rotin D; Anafi L; Avivi C; Melnichenko J; Steinberg-Silman Y; Mamtani R; Harati H; Asher N; Shapira-Frommer R; Brosh-Nissimov T; Eshet Y; Ben-Simon S; Ziv O; Khan MAW; Amit M; Ajami NJ; Barshack I; Schachter J; Wargo JA; Koren O; Markel G; Boursi B
Science; 2021 Feb; 371(6529):602-609. PubMed ID: 33303685
[TBL] [Abstract][Full Text] [Related]
19. Unbiased Microbiome and Metabolomic Profiling of Fecal Samples from Patients with Melanoma.
Bui A; Choi Y; Frankel AE; Koh AY
Methods Mol Biol; 2021; 2265():461-474. PubMed ID: 33704734
[TBL] [Abstract][Full Text] [Related]
20. Gut Microbiota in Cancer Immune Response and Immunotherapy.
Zhou CB; Zhou YL; Fang JY
Trends Cancer; 2021 Jul; 7(7):647-660. PubMed ID: 33674230
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
